- Beijing Tongrentang has reported a net income of 1.67 billion yuan for the financial year.
- The company’s revenue stood at 17.86 billion yuan.
- The firm has received 19 buys, 1 hold, and 1 sell rating from market analysts.
A look at Beijing Tongrentang Co A Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 2 | |
Dividend | 3 | |
Growth | 5 | |
Resilience | 5 | |
Momentum | 2 | |
OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Beijing Tongrentang Co A, a Chinese traditional medicine and medicinal wine company, is expected to have a positive long-term outlook, according to the Smartkarma Smart Scores. With a growth score of 5 and a resilience score of 5, the company is projected to continue expanding and weather potential challenges in the market.
In addition, Beijing Tongrentang Co A received a dividend score of 3, indicating its potential to provide stable returns to investors. However, its value and momentum scores of 2 suggest that the company may not be undervalued and may not have significant price momentum in the near future.
Overall, Beijing Tongrentang Co A‘s strong focus on Chinese traditional medicines and medicinal wines, along with its pharmaceutical retail businesses and consulting services, positions it well for long-term success and growth. Investors can expect steady returns and a resilient performance from this company in the years to come.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars